Navigation Links
Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer
Date:4/6/2009

A Drug That Improves Survival Would Earn a 50 Percent Patient Share in the U.S. and a 40 Percent Patient Share in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., April 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in stage III prostate cancer. Clinical data and the opinions of interviewed thought leaders indicate that Sanofi-Aventis's Taxotere has advantages in this attribute over LHRH agonists, including Abbott's Lupron Depot, the sales-leading agent in the market.

The new report entitled Stage III Prostate Cancer: Oncologists Ready for New Type of Therapy finds that a drug that improves five-year disease-specific survival would earn a 50 percent patient share in stage III prostate cancer in the United States and a 40 percent patient share in Europe, according to surveyed U.S. and European oncologists.

In 2007, Decision Resources' proprietary clinical gold standard for stage III prostate cancer was Lupron Depot. Based on available data and expert opinion, Ferring Pharmaceuticals' degarelix will earn gold-standard status for stage III prostate cancer in 2012. Interviewed experts anticipate that degarelix, which has competitive advantages and has shown impressive Phase III clinical trial data, will be more effective than Lupron Depot.

"Interviewed experts are optimistic about the efficacy of some emerging agents in this market, most notably degarelix and Taxotere," said Decision Resources Analyst Natalia Reoutova. "In terms of improvements to survival, Taxotere, which has been approved for use in metastatic hormone-refractory prostate cancer, remains the most promising therapy for stage III prostate cancer and some interviewed physicians are already using it off-label."

About the Report

Stage III Prostate Cancer: Oncologists Ready for New Type of Therapy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                 Decision Resources, Inc.
    Christopher Comfort                Elizabeth Marshall
    781-296-2597                       781-296-2563
    ccomfort@dresources.com            emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
2. My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise
3. National Experts Offer Practical Tips for Parents Concerned about Autism
4. Covance Experts to Present Key Insights on Risk Management at Bio/Pharmaceutical Drug Safety Forum
5. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
6. Experts turn to Web to combat distressing skin disease
7. Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
8. Experts from Africa and Asia to Discuss Maternal Health in Live Online Chat
9. FDA Experts to Speak at RAPS Horizons Conference
10. Experts Revise Guidelines on Daily Aspirin for Heart
11. Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... Houston, TX (PRWEB) , ... June 26, 2017 , ... Antoine Dental Center ... the gold standard in tooth replacement and act as a support for prosthetic teeth, such ... fuses with the existing bone and becomes a sturdy, lasting new root for the tooth. ...
(Date:6/26/2017)... ... ... LARKR™ , an innovative new smartphone app providing on-demand talk therapy, ... join its online treatment platform. , Launching in just a few days, LARKR ... of people in need nationwide, and to supplement their traditional practices. Joining this network ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut Pro ... in the timeline and write in the lyrics to any song. ProLyric flies in the ... line of the text can be added modularly for optimal control. ProLyric makes editing any ...
(Date:6/25/2017)... ... ... and the focus is on prostate cancer. Second only to skin cancer, prostate cancer ... cause of cancer related death today; lung cancer remains in the number one spot. Currently ... his lifetime. Those at highest risk are men who have a family history ...
(Date:6/24/2017)... ... , ... Doorknobs are for convenience, deadbolts are for security. , There are ... having an alarm system installed. But unless there is a working deadbolt lock that ... TX Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... Corp. is voluntarily performing a worldwide field correction of certain Intra-Aortic Balloon Pumps ... ... CS100i IABP ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX 0998-00-3023-XX;  0998-UC-3023-XX ... This field correction also applies to any System 98 or ...
(Date:6/14/2017)... 14, 2017  In 2016, Embodied Labs ... pitch competition and came away with $25,000 in seed-fund ... by Forbes as "entering the life of another" and ... teaching "empathy to medical professionals in an entirely new ... named a finalist for the Department of Education,s EdSimChallenge, ...
(Date:6/10/2017)... K. Burchfield, DPM, is recognized by Continental Who,s Who as a ... Alabama . Dr. Burchfield serves as ... over 20 years of experience, as well as expertise in the ... "The podiatry professional ... to welcome you to his practice," the company,s website states. "We ...
Breaking Medicine Technology: